The harder, less-discussed truth about BridgeBio is that the equity sitting on top of this franchise is a thin residual behind a capital structure that private-credit and private-equity sponsors engineered to harvest the ramp first.
Read Article ›The discount as struck double-counts Argentina — once in the multiple and again in the reflex to distrust cash flows that are demonstrably Brent-linked and demonstrably deleveraging the balance sheet. The tape has earned back at least one of those two discounts.
Read Article ›Quanta is priced as a high-quality compounder rather than a bargain, and the near-term estimate momentum still points up as the raised guide and the un-booked corridor stacking feed the next several prints.
Read Article ›Dave is a genuinely compounding franchise with a data moat, temporarily mispriced because the market read a high-return reinvestment decision as margin decay, carrying a real and unreserved regulatory tail that justifies a discounted multiple but not the one the market assigne...
Read Article ›The signed backlog says the consensus deceleration curve is too steep, and while that gap persists the stock can grind higher on upward revisions rather than on further multiple expansion. That is the constructive case, and it is a real one: bookings running ahead of revenue, ...
Read Article ›The market is treating a normalizing-from-peak renewable-diesel earner as a fluke and pricing the whole enterprise as a commodity rendering play, when the balance sheet is de-risking fast, the buyback retires a tenth of the float, and the collagen core compounds on its own clock.
Read Article ›The thesis lives in the hotels; the entertainment arm is a call option the market keeps trying to price and, I will argue, is getting wrong in a way that is more nuisance than opportunity.
Read Article ›The central tension on AerCap — elite, scale-leading franchise versus a perennial, structurally-justified lessor discount — resolves, on the current evidence, in favor of the franchise.
Read Article ›At roughly 26x forward free cash flow for a contracted AI franchise with a fabless cost structure and a software annuity behind it, Broadcom is worth owning for the compounding, with the clear-eyed understanding that six customers and 95% wafer concentration make the bear case...
Read Article ›At roughly 41x FY27E earnings against that growth and that balance sheet, Robinhood is mispriced as a crypto proxy when the crypto line has already fallen to 13% of revenue and the business kept compounding anyway. The market is underwriting the wrong risk, and the diversifica...
Read Article ›On July 8, 2026, Deere settled the antitrust right-to-repair lawsuit brought by the FTC and five state attorneys general; under a stipulated order running ten years and subject to FTC oversight, Deere must give farmers and independent shops the same diagnostic and repair resou...
Read Article ›The bull/bear standoff here is well worn — an elite compounding franchise trading at roughly 40x earnings against a structural share issuance overhang. That framing is the starting point, not the answer. What tips the balance is the cadence of the underlying metrics: account, ...
Read Article ›Copart just delivered revenue growth, margin expansion, and higher EPS despite falling insurance volumes, backed by record pure-sale penetration, a rising total-loss frequency that structurally feeds its inventory, and a global bidder base that props up per-car economics.
Read Article ›The market spent two years treating Comcast as a structurally challenged broadband utility with a fading media albatross stapled to it, and priced it accordingly. The separation of NBCUniversal and Sky directly attacks that framing by letting a cash-rich, under-cross-sold conn...
Read Article ›What the selloff underweights is that Microsoft has run this play before — it absorbed margin compression during the first Azure buildout and methodically clawed it back as utilization improved — and this time it holds more levers. The first is silicon. Its Cobalt CPU is now d...
Read Article ›The familiar standoff—elite CF monopoly versus a full multiple and a maturing core—resolves in the buyers' favor once you weight the catalysts by how knowable they are. CF is converting toward ALYFTREK on a long exclusivity runway and funding everything else; that is the demon...
Read Article ›For most software companies past $5 billion in ARR, the law of large numbers grinds the growth rate of *incremental* bookings steadily lower. CrowdStrike did the opposite, and management leaned into it.
Read Article ›CarMax is deliberately reshaping its earnings mix — trading retail GPU for unit growth while attempting to fund the price competitiveness through cost rather than charity.
Read Article ›The central tension in Dexcom is whether its non-insulin type 2 expansion is a margin-accretive growth wave or a commoditization trap. The resolution is in the sequencing. The catalysts that drive the next several quarters — commercial coverage of all diabetics this summer, G7...
Read Article ›The market is trading this as a comp-recovery story, and the comp has recovered, but the actual swing factor for the next leg of the stock is margin, and specifically North America margin, which is still badly depressed.
Read Article ›